(United States, Nevada, Las Vegas), DelveInsight’s, “Vasculitis – Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in the Vasculitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Over 20+ companies and 30+ pipeline drugs in Vasculitis are in various stages of development, and their anticipated acceptance in the Vasculitis market would significantly increase market revenue.
Leading Vasculitis companies developing novel drug candidates to improve the Vasculitis treatment landscape include Novartis, AbbVie, Janssen Biotech, InflaRx, Ambulero, and many others.
Promising Vasculitis pipeline therapies in various stages of development include Upadacitinib, Belimumab, Secukinumab and many others
Vasculitis involves inflammation of the blood vessels. The inflammation can cause the walls of the blood vessels to thicken, which reduces the width of the passageway through the vessel. If blood flow is restricted, it can result in organ and tissue damage. Vasculitis can affect people at any age. Some forms affect blood vessels that go to or supply specific organs like your skin, eyes, or brain. Vasculitis can have general symptoms like fever, loss of appetite, weight loss, and fatigue. Treatment depends on what’s causing your vasculitis and which organs are affected. Corticosteroid medications, also known as steroids, are generally preferred to fight inflammation.
Vasculitis Pipeline Analysis: Drug Profile
Upadacitinib(RINVOQ) was discovered and developed by AbbVie scientists.RINVOQ is a JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. Based on enzymatic and cellular assays, RINVOQ demonstrated greater inhibitory potency for JAK-1 vs. JAK-2, JAK-3, and TYK-2. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known. Phase III trials of RINVOQ in rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, giant cell arteritis, and Takayasu arteritis are ongoing.
Belimumab selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell-mediated immunity and the autoimmune response. It is being studied in the phase III stage of development for the treatment of Anti-neutrophil cytoplasmic antibody-associated Vasculitis.
Discover more about the emerging Vasculitis drugs @ Vasculitis Treatment Drugs
Vasculitis Pipeline Therapies and Key Companies
Secukinumab : Novartis
And many others
Vasculitis Pipeline Therapeutics Assessment
DelveInsight’s Report covers around 33+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued and inactive candidates
Route of Administration
Vasculitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Molecule Type: Products have been categorized under various Molecule types such as
Product Type: Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Key Vasculitis Companies: Novartis, AbbVie, Janssen Biotech, InflaRx, Ambulero, and many others.
Key Vasculitis Pipeline Therapies: Upadacitinib, Belimumab, Secukinumab, and many others
Find out more about the Vasculitis treatment options in development @ Vasculitis Clinical Trials
Table of Contents
1. Vasculitis Introduction
2. Vasculitis Executive Summary
3. Vasculitis Overview
4. Vasculitis Pipeline Therapeutics
5. Vasculitis Late-Stage Products (Phase III)
6. Vasculitis Mid-Stage Products (Phase II)
7. Vasculitis Early Stage Products (Phase I/II)
8. Vasculitis Preclinical Stage Products
9. Vasculitis Discovery Stage Products
10. Vasculitis Therapeutic Assessment
11. Vasculitis Inactive Products
12. Vasculitis Collaborations Assessment- Licensing / Partnering / Funding
13. Vasculitis Unmet Needs
14. Vasculitis Market Drivers and Barriers
16. About DelveInsight
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States